Loading…
Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study
Background In this study we investigate the prediction and prognostic value of CXCL8–CXCR1/2 axis for Triple-negative breast cancer (TNBC) patients underwent neoadjuvant chemotherapy (NAC) following standard radical surgery. Methods A total of 303 TNBC patients were included in this study. The NAC r...
Saved in:
| Published in: | Breast cancer research and treatment 2020-06, Vol.181 (3), p.561-570 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c473t-977b00f405dc9365b76ee1720754e5d391caed9b42e663d28cfb24ee9ffc32083 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c473t-977b00f405dc9365b76ee1720754e5d391caed9b42e663d28cfb24ee9ffc32083 |
| container_end_page | 570 |
| container_issue | 3 |
| container_start_page | 561 |
| container_title | Breast cancer research and treatment |
| container_volume | 181 |
| creator | Wang, Ruo-Xi Ji, Peng Gong, Yue Shao, Zhi-Ming Chen, Sheng |
| description | Background
In this study we investigate the prediction and prognostic value of CXCL8–CXCR1/2 axis for Triple-negative breast cancer (TNBC) patients underwent neoadjuvant chemotherapy (NAC) following standard radical surgery.
Methods
A total of 303 TNBC patients were included in this study. The NAC regimen was weekly paclitaxel plus carboplatin (PC) for all patients. Serum CXCL8 level was measured at baseline and at surgery via Enzyme-linked immunosorbent assay (ELISA). Immunohistochemistry was used to detect CXCR1 and CXCR2 expression in patients with residual tumors after NAC. Correlations between variables and treatment response were studied, and Cox proportional hazards regression analysis was implemented for prognostic evaluation.
Results
Of the 303 patients, 103 (34.0%) patients experienced pathological complete response (pCR) after completion of NAC. CXCL8 level was significantly upgraded after NAC in CXCR1/2+ patients and downgraded after NAC in CXCR1/2− patients. Higher pCR rate was more likely observed in patients with lower CXCL8 level at surgery (
P
= 0.004, HR 0.939, 95% CI 0.900–0.980). In the multivariate survival model, CXCR1/2 expression was of an independent prognostic value for survival (CXCR1/2+, HR 2.149, 95% CI 0.933–4.949; CXCR1/2++, HR 3.466, 95% CI 1.569–7.655, CXCR1/2− was used as a reference;
P
= 0.003). Patients with higher level of CXCR1/2 expression were more likely to suffer unfavorable outcome.
Conclusions
This study contributes to the clarification of the value of serum CXCL8 level to predict pCR for TNBC patients, and prognostic performance of CXCR1/2 in non-pCR responders after NAC. The CXCL8–CXCR1/2 might play an important role in tailoring and modifying the NAC strategy for advanced TNBCs; however, further confirmatory studies are needed. |
| doi_str_mv | 10.1007/s10549-020-05660-z |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2398164330</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A623827720</galeid><sourcerecordid>A623827720</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-977b00f405dc9365b76ee1720754e5d391caed9b42e663d28cfb24ee9ffc32083</originalsourceid><addsrcrecordid>eNp9kt9qFDEUxgdRbK2-gBcSEIo3054kM8mMd2XxHywIouJdyGTO7GaZTcYkU9xe6TP4hj6JabdaKyK5OHDO7zucL3xF8ZjCCQWQp5FCXbUlMCihFgLKizvFIa0lLyWj8m5xCFTIUjQgDooHMW4AoJXQ3i8OOOOCNlV7WHz7qMcZiR_I4tNi2fz4-j3Xd_SUEf3FRmIdceh1v5nPtUvErHHr0xqDnnZk8IGkYKcRS4crnew5ki6gjpnTzmAgU26iS_E50SRgCj5OaK64yY4-kZjmfvewuDfoMeKj63pUfHj54v3idbl8--rN4mxZmkryVLZSdgBDBXVvWi7qTgpEKhnIusK65y01Gvu2qxgKwXvWmKFjFWI7DIYzaPhR8Wy_dwr-84wxqa2NBsdRZ4dzVIy3DRUV55DRp3-hGz8Hl69TrALGaqgZv6FWekRl3eBT0OZyqToTjDdM5usydfIPKr8et9Z4h4PN_VuC4z8Ea9RjWkc_zsl6F2-DbA-a_LEx4KCmYLc67BQFdRkQtQ-IygFRVwFRF1n05Nra3G2x_y35lYgM8D0Q88itMNx4_8_an9VRxW4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2402250523</pqid></control><display><type>article</type><title>Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study</title><source>Springer Link</source><creator>Wang, Ruo-Xi ; Ji, Peng ; Gong, Yue ; Shao, Zhi-Ming ; Chen, Sheng</creator><creatorcontrib>Wang, Ruo-Xi ; Ji, Peng ; Gong, Yue ; Shao, Zhi-Ming ; Chen, Sheng</creatorcontrib><description>Background
In this study we investigate the prediction and prognostic value of CXCL8–CXCR1/2 axis for Triple-negative breast cancer (TNBC) patients underwent neoadjuvant chemotherapy (NAC) following standard radical surgery.
Methods
A total of 303 TNBC patients were included in this study. The NAC regimen was weekly paclitaxel plus carboplatin (PC) for all patients. Serum CXCL8 level was measured at baseline and at surgery via Enzyme-linked immunosorbent assay (ELISA). Immunohistochemistry was used to detect CXCR1 and CXCR2 expression in patients with residual tumors after NAC. Correlations between variables and treatment response were studied, and Cox proportional hazards regression analysis was implemented for prognostic evaluation.
Results
Of the 303 patients, 103 (34.0%) patients experienced pathological complete response (pCR) after completion of NAC. CXCL8 level was significantly upgraded after NAC in CXCR1/2+ patients and downgraded after NAC in CXCR1/2− patients. Higher pCR rate was more likely observed in patients with lower CXCL8 level at surgery (
P
= 0.004, HR 0.939, 95% CI 0.900–0.980). In the multivariate survival model, CXCR1/2 expression was of an independent prognostic value for survival (CXCR1/2+, HR 2.149, 95% CI 0.933–4.949; CXCR1/2++, HR 3.466, 95% CI 1.569–7.655, CXCR1/2− was used as a reference;
P
= 0.003). Patients with higher level of CXCR1/2 expression were more likely to suffer unfavorable outcome.
Conclusions
This study contributes to the clarification of the value of serum CXCL8 level to predict pCR for TNBC patients, and prognostic performance of CXCR1/2 in non-pCR responders after NAC. The CXCL8–CXCR1/2 might play an important role in tailoring and modifying the NAC strategy for advanced TNBCs; however, further confirmatory studies are needed.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-020-05660-z</identifier><identifier>PMID: 32361849</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adjuvant treatment ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor - metabolism ; Breast cancer ; Cancer ; Cancer patients ; Cancer research ; Carboplatin ; Carboplatin - administration & dosage ; Care and treatment ; Chemotherapy ; CXCR2 protein ; Development and progression ; Enzyme-linked immunosorbent assay ; Enzymes ; Female ; Follow-Up Studies ; Humans ; Immunohistochemistry ; Interleukin-8 - metabolism ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoadjuvant Therapy - mortality ; Oncology ; Oncology, Experimental ; Paclitaxel ; Paclitaxel - administration & dosage ; Patients ; Pilot Projects ; Preclinical Study ; Prognosis ; Receptors, Interleukin-8A - metabolism ; Receptors, Interleukin-8B - metabolism ; Retrospective Studies ; Surgery ; Survival ; Survival Rate ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - metabolism ; Triple Negative Breast Neoplasms - pathology ; Tumors</subject><ispartof>Breast cancer research and treatment, 2020-06, Vol.181 (3), p.561-570</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-977b00f405dc9365b76ee1720754e5d391caed9b42e663d28cfb24ee9ffc32083</citedby><cites>FETCH-LOGICAL-c473t-977b00f405dc9365b76ee1720754e5d391caed9b42e663d28cfb24ee9ffc32083</cites><orcidid>0000-0003-3530-1287</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32361849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Ruo-Xi</creatorcontrib><creatorcontrib>Ji, Peng</creatorcontrib><creatorcontrib>Gong, Yue</creatorcontrib><creatorcontrib>Shao, Zhi-Ming</creatorcontrib><creatorcontrib>Chen, Sheng</creatorcontrib><title>Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Background
In this study we investigate the prediction and prognostic value of CXCL8–CXCR1/2 axis for Triple-negative breast cancer (TNBC) patients underwent neoadjuvant chemotherapy (NAC) following standard radical surgery.
Methods
A total of 303 TNBC patients were included in this study. The NAC regimen was weekly paclitaxel plus carboplatin (PC) for all patients. Serum CXCL8 level was measured at baseline and at surgery via Enzyme-linked immunosorbent assay (ELISA). Immunohistochemistry was used to detect CXCR1 and CXCR2 expression in patients with residual tumors after NAC. Correlations between variables and treatment response were studied, and Cox proportional hazards regression analysis was implemented for prognostic evaluation.
Results
Of the 303 patients, 103 (34.0%) patients experienced pathological complete response (pCR) after completion of NAC. CXCL8 level was significantly upgraded after NAC in CXCR1/2+ patients and downgraded after NAC in CXCR1/2− patients. Higher pCR rate was more likely observed in patients with lower CXCL8 level at surgery (
P
= 0.004, HR 0.939, 95% CI 0.900–0.980). In the multivariate survival model, CXCR1/2 expression was of an independent prognostic value for survival (CXCR1/2+, HR 2.149, 95% CI 0.933–4.949; CXCR1/2++, HR 3.466, 95% CI 1.569–7.655, CXCR1/2− was used as a reference;
P
= 0.003). Patients with higher level of CXCR1/2 expression were more likely to suffer unfavorable outcome.
Conclusions
This study contributes to the clarification of the value of serum CXCL8 level to predict pCR for TNBC patients, and prognostic performance of CXCR1/2 in non-pCR responders after NAC. The CXCL8–CXCR1/2 might play an important role in tailoring and modifying the NAC strategy for advanced TNBCs; however, further confirmatory studies are needed.</description><subject>Adjuvant treatment</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Carboplatin</subject><subject>Carboplatin - administration & dosage</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>CXCR2 protein</subject><subject>Development and progression</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Enzymes</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Interleukin-8 - metabolism</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy - mortality</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Paclitaxel</subject><subject>Paclitaxel - administration & dosage</subject><subject>Patients</subject><subject>Pilot Projects</subject><subject>Preclinical Study</subject><subject>Prognosis</subject><subject>Receptors, Interleukin-8A - metabolism</subject><subject>Receptors, Interleukin-8B - metabolism</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Triple Negative Breast Neoplasms - metabolism</subject><subject>Triple Negative Breast Neoplasms - pathology</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kt9qFDEUxgdRbK2-gBcSEIo3054kM8mMd2XxHywIouJdyGTO7GaZTcYkU9xe6TP4hj6JabdaKyK5OHDO7zucL3xF8ZjCCQWQp5FCXbUlMCihFgLKizvFIa0lLyWj8m5xCFTIUjQgDooHMW4AoJXQ3i8OOOOCNlV7WHz7qMcZiR_I4tNi2fz4-j3Xd_SUEf3FRmIdceh1v5nPtUvErHHr0xqDnnZk8IGkYKcRS4crnew5ki6gjpnTzmAgU26iS_E50SRgCj5OaK64yY4-kZjmfvewuDfoMeKj63pUfHj54v3idbl8--rN4mxZmkryVLZSdgBDBXVvWi7qTgpEKhnIusK65y01Gvu2qxgKwXvWmKFjFWI7DIYzaPhR8Wy_dwr-84wxqa2NBsdRZ4dzVIy3DRUV55DRp3-hGz8Hl69TrALGaqgZv6FWekRl3eBT0OZyqToTjDdM5usydfIPKr8et9Z4h4PN_VuC4z8Ea9RjWkc_zsl6F2-DbA-a_LEx4KCmYLc67BQFdRkQtQ-IygFRVwFRF1n05Nra3G2x_y35lYgM8D0Q88itMNx4_8_an9VRxW4</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Wang, Ruo-Xi</creator><creator>Ji, Peng</creator><creator>Gong, Yue</creator><creator>Shao, Zhi-Ming</creator><creator>Chen, Sheng</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3530-1287</orcidid></search><sort><creationdate>20200601</creationdate><title>Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study</title><author>Wang, Ruo-Xi ; Ji, Peng ; Gong, Yue ; Shao, Zhi-Ming ; Chen, Sheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-977b00f405dc9365b76ee1720754e5d391caed9b42e663d28cfb24ee9ffc32083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adjuvant treatment</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Carboplatin</topic><topic>Carboplatin - administration & dosage</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>CXCR2 protein</topic><topic>Development and progression</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Enzymes</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Interleukin-8 - metabolism</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy - mortality</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Paclitaxel</topic><topic>Paclitaxel - administration & dosage</topic><topic>Patients</topic><topic>Pilot Projects</topic><topic>Preclinical Study</topic><topic>Prognosis</topic><topic>Receptors, Interleukin-8A - metabolism</topic><topic>Receptors, Interleukin-8B - metabolism</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Triple Negative Breast Neoplasms - metabolism</topic><topic>Triple Negative Breast Neoplasms - pathology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Ruo-Xi</creatorcontrib><creatorcontrib>Ji, Peng</creatorcontrib><creatorcontrib>Gong, Yue</creatorcontrib><creatorcontrib>Shao, Zhi-Ming</creatorcontrib><creatorcontrib>Chen, Sheng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Ruo-Xi</au><au>Ji, Peng</au><au>Gong, Yue</au><au>Shao, Zhi-Ming</au><au>Chen, Sheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>181</volume><issue>3</issue><spage>561</spage><epage>570</epage><pages>561-570</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Background
In this study we investigate the prediction and prognostic value of CXCL8–CXCR1/2 axis for Triple-negative breast cancer (TNBC) patients underwent neoadjuvant chemotherapy (NAC) following standard radical surgery.
Methods
A total of 303 TNBC patients were included in this study. The NAC regimen was weekly paclitaxel plus carboplatin (PC) for all patients. Serum CXCL8 level was measured at baseline and at surgery via Enzyme-linked immunosorbent assay (ELISA). Immunohistochemistry was used to detect CXCR1 and CXCR2 expression in patients with residual tumors after NAC. Correlations between variables and treatment response were studied, and Cox proportional hazards regression analysis was implemented for prognostic evaluation.
Results
Of the 303 patients, 103 (34.0%) patients experienced pathological complete response (pCR) after completion of NAC. CXCL8 level was significantly upgraded after NAC in CXCR1/2+ patients and downgraded after NAC in CXCR1/2− patients. Higher pCR rate was more likely observed in patients with lower CXCL8 level at surgery (
P
= 0.004, HR 0.939, 95% CI 0.900–0.980). In the multivariate survival model, CXCR1/2 expression was of an independent prognostic value for survival (CXCR1/2+, HR 2.149, 95% CI 0.933–4.949; CXCR1/2++, HR 3.466, 95% CI 1.569–7.655, CXCR1/2− was used as a reference;
P
= 0.003). Patients with higher level of CXCR1/2 expression were more likely to suffer unfavorable outcome.
Conclusions
This study contributes to the clarification of the value of serum CXCL8 level to predict pCR for TNBC patients, and prognostic performance of CXCR1/2 in non-pCR responders after NAC. The CXCL8–CXCR1/2 might play an important role in tailoring and modifying the NAC strategy for advanced TNBCs; however, further confirmatory studies are needed.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32361849</pmid><doi>10.1007/s10549-020-05660-z</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-3530-1287</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2020-06, Vol.181 (3), p.561-570 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2398164330 |
| source | Springer Link |
| subjects | Adjuvant treatment Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - metabolism Breast cancer Cancer Cancer patients Cancer research Carboplatin Carboplatin - administration & dosage Care and treatment Chemotherapy CXCR2 protein Development and progression Enzyme-linked immunosorbent assay Enzymes Female Follow-Up Studies Humans Immunohistochemistry Interleukin-8 - metabolism Medicine Medicine & Public Health Middle Aged Neoadjuvant Therapy - mortality Oncology Oncology, Experimental Paclitaxel Paclitaxel - administration & dosage Patients Pilot Projects Preclinical Study Prognosis Receptors, Interleukin-8A - metabolism Receptors, Interleukin-8B - metabolism Retrospective Studies Surgery Survival Survival Rate Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - metabolism Triple Negative Breast Neoplasms - pathology Tumors |
| title | Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A52%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Value%20of%20CXCL8%E2%80%93CXCR1/2%20axis%20in%20neoadjuvant%20chemotherapy%20for%20triple-negative%20breast%20cancer%20patients:%20a%20retrospective%20pilot%20study&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Wang,%20Ruo-Xi&rft.date=2020-06-01&rft.volume=181&rft.issue=3&rft.spage=561&rft.epage=570&rft.pages=561-570&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-020-05660-z&rft_dat=%3Cgale_proqu%3EA623827720%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c473t-977b00f405dc9365b76ee1720754e5d391caed9b42e663d28cfb24ee9ffc32083%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2402250523&rft_id=info:pmid/32361849&rft_galeid=A623827720&rfr_iscdi=true |